You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聖諾醫藥-B(02257.HK)啟動用於醫美治療成人腹部減脂整形臨床研究
阿思達克 05-30 12:19
聖諾醫藥-B(02257.HK)公布,啟動一項siRNA(小干擾RNA)的I期臨床試驗,應用候選藥物STP705對成人實施腹部整形以減少頦下脂肪。該項研究是Sirnaomics首次嘗試將RNAi治療產品應用於醫學美容治療。 公司指出,STP705利用雙靶向抑制特性和多(月太)納米顆粒(PNP)增強遞送來直接敲低TGF-β1和COX-2基因表達。STP705目前針對不同的適應症進行五項臨床試驗:一項IIa期臨床試驗針對鱗狀細胞原位癌(isSCC),一項治療基底細胞癌(BCC)的II期臨床試驗,一項治療瘢痕疙瘩的I/II期臨床試驗,一項治療增生性瘢痕的I/II期臨床試驗,以及一項治療肝癌的I期臨床試驗。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account